Company / Revenue per Share
Haemonetics Revenue per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$26.97
FY2024
5-year range
$19.34 / $26.97
FY2020-FY2024
Trend
+5.9%
vs FY2023
Sector context
#68 of 147
Health Care
What the data says
At $26.97, Haemonetics's revenue per share ranks #68 of 147 in the Health Care sector. Revenue per Share has increased for 4 consecutive years, from $4.43 in FY2017 to $26.97 in FY2024.
Based on SEC 10-K filings.
26.97 in FY2024 with a 3-year CAGR of +11.7%.
Improved from $22.73 to $26.97 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +11.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#68 of 147 in Health CareTop 46% of 147This company $26.97 Sector average $128.17
▼
-79.0% below sector average
Key checks
Key Insights
- Haemonetics's revenue per share has grown for 3 consecutive years.
- In FY2024, revenue per share increased 5.9% year-over-year.
- Ranks #68 out of 147 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $26.97 | +5.9% |
| FY2023 | $25.47 | +12.1% |
| FY2022 | $22.73 | +17.5% |
| FY2021 | $19.34 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $4.43 | -74.2% |
| FY2016 | $17.15 | -1.8% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026